Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.53 |
| ▸ | MYLK | Q15746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 7/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.51 |
| ▸ | THPO | P40225 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456881 | 1.00 | CYP1A2 (0.56) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3133065 | 0.89 | CDK2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL29904571 | 0.89 | CDK2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL639819 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2230689 | 0.81 | CDK2 (0.62) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3057460 | 0.81 | TTR (0.60) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14030904 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11048086 | 0.80 | HSD17B10 (0.39) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28784525 | 0.79 | CDK2 (0.60) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28234846 | 0.79 | TTR (0.58) | CYP1A2CYP2A6CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546572-A | Novel naphthyl and isoquinoline sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240130367-A1 | PLANT GROWTH PROMOTERS | UNIVERSITY OF DURHAM (GB) | 2024-04-25 | — | — | US | disclosed |
| EP-4019022-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2024-01-31 | — | — | EP | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116916750-A | plant growth promoter | 杜伦大学 | 2023-10-20 | — | — | CN | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-1996040641-A1 | SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | disclosed |
| EP-0602028-B1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO WEDROPHARM GMBH (DE) | 1996-01-17 | — | — | EP | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0602028-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | PHARNO WEDROPHARM GMBH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993005014-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO-WEDROPHARM GMBH (DE) | 1993-03-18 | — | — | WO | disclosed |
| EP-0462179-A4 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | — | 1992-03-18 | — | — | EP | disclosed |
| EP-0462179-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-27 | — | — | EP | disclosed |
| WO-1990009787-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-09-07 | — | — | WO | disclosed |
| US-4069254-A | INHIBITORS OF BLOOD PLATELET AGGREGATION | BANYU PHARMACEUTICAL CO., LTD. (JA) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | CYP1A2 520/4885CYP2A6 868/4885CYP3A4 713/4885 |
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CYP1A2 1483/4885CYP2A6 1221/4885CYP3A4 1452/4885 |
| US-20240130367-A1 | PLANT GROWTH PROMOTERS | MYCBP, GLB1, GUSB | CYP1A2 1310/4885CYP2A6 1604/4885CYP3A4 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.